San Diego, CA -- (SBWIRE) -- 10/10/2016 -- An investigation on behalf of investors of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential securities laws violations by Alnylam Pharmaceuticals and certain of its directors and officers was announced.

Investors who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on whether a series of statements by Alnylam Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 10, 2016, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALN)Y announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) declined to as low as $33.16 per share on October 7, 2016.

Those who purchased shares of Alnylam Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com